ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 477

Inflammation but Also Pain and Function, and Psychological Impact Is Related to Non-Acceptable Status in Patients with Rheumatoid Arthritis: A Factorial Analysis in 643 Patients

Catia Duarte1, Eduardo Santos 2, Eirik Kristianslund 3, Turid Heiberg 4, Maarten de Wit 5, Maxime Dougados 6, Tore Kvien 7, Laure Gossec 8 and Jose Pereira da Silva 9, 1Department of Rheumatology, Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal, 2Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, 4Department for Research and Education, Oslo University Hospital, Oslo, Norway, 5Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, 6Cochin Hospital, Paris, France, 7Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 8Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 9Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: non-PASS and Factorial Analysis, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient Acceptable Symptom State (PASS) represents the maximum level of symptom intensity that a patient considers acceptable. Control of disease activity is associated with the attainment of PASS, but many patients do not reach this status despite being in disease remission. Recognizing the factors associated with PASS status can be helpful in identifying the need for adjunctive treatments besides immunosuppressive therapy, aiming at improving the satisfaction and well-being of patients with rheumatoid arthritis (RA). This study aimed to explore domains of health associated with being in non-PASS in RA patients.

Methods: Data of patients with a diagnosis of RA from 3 databases (NOR-DMARD, RAID study and RAID.Pt) were included. PASS was assessed using the anchored method based on patients’ perspective, through the question: “Think about all the ways your RA has affected you during the last week. If you were to remain for the next few months as you were during the last week, would this be a) Acceptable b) Unacceptable”. Age, gender, disease duration, disease activity based on DAS28-3 variable (joint counts and ESR) and its individual components, the RA Impact of Disease (RAID) score and its individual components, Patient Global Assessment (PGA) and Physician Global Assessment (PHGA) were collected. Patients who considered themselves in a non-acceptable status and without missing data were selected for statistical analysis. An exploratory factor analysis using the principal components method and Varimax rotation with Kaiser Normalization was performed. A correlation analysis (Pearson’s correlation) between the identified factors with PGA and PhGA was performed.

Results: In total, 643 RA patients in non-acceptable status from the three datasets (NOR-DMARD: 388; RAID Study: 179 and RAID.Pt: 76) were included (female: 79.6%, mean age (±SD): 54.0±15.2 years; mean disease duration: 13.4±1.5 years). On average, patients in non-PASS status scored ≥ to 5 in all RAID domains, except Coping (mean:4.79±2.33) and had moderate disease activity (mean DAS28-ESR-3v: 3.77±1.46). Three principal components were identified: “Psychological Impact”, “Pain and Function”, and “Inflammation” explaining respectively 32.3%, 31.7%, and 12.9% of the total variance (table 1). PGA was moderately correlated with  ”Psychological Component” (r= 0.43) and with “Pain and Function Component” (r=0.68), but not with the  “Inflammation Component”. Conversely, PhGA correlated moderately with the “Inflammation component” (r=0.55), but not with the other two factors.

Conclusion: This exploratory analysis suggested that non-PASS status can be due to three main factors: “Psychological impact”, “Pain and Function and Inflammation. This suggests the need for a holistic evaluation and consideration of tailored interventions to optimize outcomes, from the patients’ perspective.


Disclosure: C. Duarte, None; E. Santos, None; E. Kristianslund, None; T. Heiberg, None; M. de Wit, Abbvie, 5, 8, BMS, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Janssen-Cilag, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8; M. Dougados, AbbVie, 2, 5, 8, Amgen, 5, Biogen, 5, BMS, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, Merck, 2, 5, Merck Inc, 2, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; T. Kvien, AbbVie, 2, 8, Biogen, 5, 8, Biogen, Egis, Eli Lilly, Hikma, Mylan, Novartis/Sandoz, Oktal, Hospira/Pfizer, Sanofi and UCB, 5, BMS, 8, Celltrion, 8, Egis, 5, 8, Eli Lilly, 5, 8, Hikma, 5, 8, Hospira/Pfizer, 2, 5, 8, MSD, 2, 8, Mylan, 5, 8, Novartis, 8, Novartis/Sandoz, 5, 8, Oktal, 5, 8, Orion Pharma, 8, Roche, 2, 8, Sandoz, 8, Sanofi, 5, 8, UCB, 5, 8; L. Gossec, Abbvie, 5, AbbVie, 5, Abbvie, Biogen, BMS, Celgene, Lilly, Novartis, Pfizer, SAnofi-Aventis, UCB, 5, Amgen, 5, Biogen, 5, BMS, 2, 5, Celgene, 5, Celgene Corporation, 2, Janssen, 5, Lilly, 2, 5, MSD, 5, Nordic Pharma, 5, Novartis, 5, Pfizer, 2, 5, Sanofi, 5, Sanofi-Aventis, 5, UCB, 5; J. Pereira da Silva, None.

To cite this abstract in AMA style:

Duarte C, Santos E, Kristianslund E, Heiberg T, de Wit M, Dougados M, Kvien T, Gossec L, Pereira da Silva J. Inflammation but Also Pain and Function, and Psychological Impact Is Related to Non-Acceptable Status in Patients with Rheumatoid Arthritis: A Factorial Analysis in 643 Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/inflammation-but-also-pain-and-function-and-psychological-impact-is-related-to-non-acceptable-status-in-patients-with-rheumatoid-arthritis-a-factorial-analysis-in-643-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammation-but-also-pain-and-function-and-psychological-impact-is-related-to-non-acceptable-status-in-patients-with-rheumatoid-arthritis-a-factorial-analysis-in-643-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology